
OSE Immunotherapeutics SA
PAR:OSE

OSE Immunotherapeutics SA
Total Liabilities & Equity
OSE Immunotherapeutics SA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
OSE Immunotherapeutics SA
PAR:OSE
|
Total Liabilities & Equity
€140.9m
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
![]() |
Valneva SE
PAR:VLA
|
Total Liabilities & Equity
€500m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
![]() |
Nanobiotix SA
PAR:NANO
|
Total Liabilities & Equity
€86.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities & Equity
€194.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
10%
|
|
![]() |
Inventiva SA
PAR:IVA
|
Total Liabilities & Equity
€39.4m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
![]() |
Eurobio Scientific SA
PAR:ALERS
|
Total Liabilities & Equity
€313.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
34%
|
CAGR 10-Years
22%
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

See Also
What is OSE Immunotherapeutics SA's Total Liabilities & Equity?
Total Liabilities & Equity
140.9m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Total Liabilities & Equity amounts to 140.9m EUR.
What is OSE Immunotherapeutics SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
8%
Over the last year, the Total Liabilities & Equity growth was 75%. The average annual Total Liabilities & Equity growth rates for OSE Immunotherapeutics SA have been 13% over the past three years , 8% over the past five years .